FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

Retreat 2020 in times of Corona

Coronavirus

Coronavirus

A few days before the FOR2240 wanted to have the retreat in a cozy cottage in Bedburg (https://danielshof.de/), the Corona wave started to hit Cologne. Consequently, every larger meeting had to be canceled and the FOR2240 held a small full-day meeting – only the principal investigators – in the Lecture Room of the Department of Ophthalmology. All the necessary precautions were taken very seriously during the gathering – such as keeping distance, no handshake, etc.
All principal investigators of the funding period presented and discussed the results of their projects. Titles included: „Personalized Immunomodulation in High-Risk Corneal Transplantation”, “Identification of novel endogenous modulators of developmental and inflammatory lymphangiogenesis by analyzing mouse strain-specific differences”, “Ocular GvHD”, “Myeloid cell function in corneal hem- and lymphangiogenesis”; “Midkine mediates metastasis in uveal melanoma by modulation of Notch2 signaling”, “Microglia in AMD” and “Potential new/affiliated projects”. Afterward, the Principal Investigators had a discussion about the planned SFB application and strategic actions to be taken.
FOR2240 also had the chance to welcome a new member – the successor of Dr. Jens Horstmann – Ph.D. Gwen Musial from the USA. She was appointed to the new project as the investigator of the C1 Project (Cologne Experimental Eye Imaging Center).
“Potential new/affiliated projects”. Afterward the Principal Investigators had a discussion about the planned SFB application and strategic actions to be taken.

Related posts

Claus Cursiefen

Claus Cursiefen

January 7, 2023

Rare eye diseases: Eight million euros for research: Funding for four years


Read more
December 15, 2022

Experimental Glaucoma Research Group awarded and funded


Read more
howald
November 17, 2020

Antonia Howaldt accepted into the Cologne Clinician Scientist Program


Read more

News

  • Rare eye diseases: Eight million euros for research: Funding for four years
  • Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface
  • Experimental Glaucoma Research Group awarded and funded
  • Leonhard Klein-Preis for Prof. Matthaei
  • 4th Shanghai-Cologne Scientific Symposium

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck